Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer

This publication has 8 references indexed in Scilit:

• Endocrinology: The effects of ICI 182, 780, a pure anti-oestrogen, on the hypothalamic-pituitary—gonadal axis and on endometrial proliferation in pre-menopausal women
  Human Reproduction, 1994
• Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro
  British Journal of Cancer, 1994
• Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer.
  Journal of Clinical Oncology, 1993
• Original article: Response after withdrawal of tamoxifen and progestogens in advanced breast cancer
  Annals of Oncology, 1992
• Acquired Tamoxifen Resistance: Correlation With Reduced Breast Tumor Levels of Tamoxifen and Isomerization of Trans-4-Hydroxytamoxifen
  JNCI Journal of the National Cancer Institute, 1991
• Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization.
  Proceedings of the National Academy of Sciences, 1990
• Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen.
  The EMBO Journal, 1990
• The definition of the ‘no change’ category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast
  European Journal of Cancer and Clinical Oncology, 1988